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DOI 10.1186/s12967-014-0359-yRESEARCH Open AccessIntra-tumoural vessel area estimated by expression
of epidermal growth factor-like domain 7 and
microRNA-126 in primary tumours and metastases
of patients with colorectal cancer: a descriptive
study
Torben Frøstrup Hansen1,4*, Boye Schnack Nielsen2, Anders Jakobsen1,4 and Flemming Brandt Sørensen3,4Abstract
Background: Understanding the biological properties of potential drug targets are important. This is especially
true for anti-angiogenic therapies in the search for potential biomarkers. The aim of the present descriptive study was
to analyse the intra-tumoural expressions of epidermal growth factor-like domain 7 (EGFL7) and microRNA-126
(miRNA-126) in primary tumours from patients with stage II-IV colorectal cancer (CRC) and in paired samples of primary
tumours, regional lymph node metastases and distant metastases.
Methods: A total of 126 patients were included. Analyses were performed on resections of primary tumours, regional
lymph node metastases, and large needle biopsies from distant metastases. EGFL7 was analysed by immunohistochemistry
(IHC) and miRNA-126 by in situ hybridization (ISH). Both biomarkers were quantified by image guided analyses to
determine the relative fraction estimates of vessel areas (VA).
Results: The intra-tumoural EGFL7 VA was significantly higher in primary tumours from patients with recurrent
disease than in patients without relapse in both stage II and III, p = 0.019 and p = 0.001, respectively. The EGFL7
VA was significantly higher and the miRNA-126 VA significantly lower in regional lymph node metastases compared to
primary tumours, p = 0.01 and p < 10−6, respectively. Furthermore, the miRNA-126 VA in liver metastases was
significantly lower than in the primary tumours, p = 0.02.
Conclusion: The intra-tumoural expression of EGFL7 in early stages of CRC may influence the risk of post-surgical
recurrence. Differential expression of miRNA-126 seems more pronounced in disseminated disease, which supports its
role as a regulator in the metastatic process.
Keywords: Angiogenesis, Colorectal neoplasms, Epidermal growth factor like domain 7, Metastases, microRNA-126Background
Targeting angiogenesis is a well established strategy in
the treatment of patients with metastatic colorectal can-
cer (mCRC) and the clinical benefit is well documented
[1,2]. The initial experiences were based on an antibody
targeting the vascular endothelial growth factor A* Correspondence: torben.hansen@rsyd.dk
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unless otherwise stated.(VEGF-A), one of the most important growth factors in
the onset of the angiogenic process [3,4]. The clinical
benefit, however, of targeting VEGF-A is rather limited
and may be restricted to a subgroup of patients, and
new strategies for controlling tumour angiogenesis are
constantly being evaluated.
One strategy, currently under investigation in clinical tri-
als, is the targeting of another important pro-angiogenic
protein, the epidermal growth factor-like domain 7 (EGFL7).
The EGFL7 gene was identified around 2003 and the gene
product was characterised as a protein restricted to the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Sample distributions according to location and analysed
parameters. (EGFL7: Epidermal growth factor-like domain 7; miRNA-126:
microRNA-126).
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The expression of EGFL7 is up-regulated during patho-
physiological angiogenesis [8], where it is secreted to
the extracellular matrix (ECM), and guides the vascular
sprouting process [9]. EGFL7 is important for tubulo-
genesis [6] and is able to inhibit endothelial cell (EC)
adhesion molecules causing blood vessels to become
leaky [10]. In human cancers elevated levels of EGFL7,
assessed by immunohistochemistry (IHC) as well as
qPCR, have been associated with increased risk of
metastatic spread in several solid tumours [10-13].
However, the evidence on EGFL7 in colorectal cancer
(CRC) is still very sparse [11,14].
Another therapeutic strategy that may become available
in the near future is the targeting of microRNA (miRNA).
In the context of anti-angiogenic therapy miRNA-126 re-
placement may constitute an exiting approach. The
miRNA-126 is a highly EC specific miRNA [15,16] regulat-
ing EC proliferation, migration, and survival by modulating
VEGF-A and angiopoietin 1 driven signalling cascades
[17-20]. Regulating blood vessel integrity and extravasation
of inflammatory cells into the tumour compartment con-
stitute other functions regulated by this miRNA [17,18,21].
MicroRNA-126 is encoded by intron 7 of the EGFL7 gene
[18], and the EGFL7 mRNA is suggested to constitute one
of its many targets [22], adding complexity to the interplay
of this angiogenic couple. The clinical evidence on
miRNA-126 in CRC argues for a deregulated expression in
tumour tissue [23,24] and a possible clinical importance at
both early and advanced stages of the disease [11,14,25,26].
We have previously shown that high miRNA-126 ex-
pression in primary tumours, determined by in situ
hybridization (ISH) analysis, is predictive of response to
chemotherapy in mCRC [25], and that this association
is related to miRNA-126 and not the general vascular
density in the tumours [27], indicating that the
miRNA-126 related vascularisation of primary tumours
is an important predictor of response to therapeutic
intervention.
Translational studies in mCRC are often based on ana-
lyses of the resected primary tumour. Whether these re-
sults can be extrapolated to the metastatic lesions that are
targeted by the treatment, is often unknown. Analysing
putative biomarkers in paired samples of metastases and
primary tumours may thus provide useful biological
insight. Furthermore, analysing biomarker expression at
earlier disease stages may likewise be of importance, when
evaluating the therapeutic potential of the given pathway
in an adjuvant setting.
The aim of this descriptive study was to analyse the
expression of EGFL7 and miRNA-126 in the primary
tumours of stage II-IV CRC and whether this expres-
sion changed in paired samples of primary tumours, re-
gional lymph node metastases and distant metastases.Methods
Reporting in this study is in accordance with the BRIS-
QUE criteria [28].Patient characteristics
This biology focused, descriptive study included patients
with histologically verified CRC stage II-IV. Patients were
selected according to the following criteria: Patients with
stage II or III disease followed for at least 6 years after sur-
gery without any sign of relapse, patients with stage II or
III disease with histologically verified relapse at distant
organ sites within 6 years after surgery, and patients with
primary disseminated disease (stage IV). A total of 126 pa-
tients were retrospectively included. All patients had their
primary tumour surgically removed. Regional lymph node
metastases and distant metastases (synchronous and
metachronous) were collected if available (Figure 1).
Patients were operated at six different centres in Denmark
between June 1998 and July 2012.
The study was approved by the Regional Scientific Eth-
ical Committee and the Danish Data Protection Agency
(20010078, S-20080104, S-20100005, VF-20060115, 2007-
41-0252), and written informed consent was obtained
from all patients enrolled in the study.Sampling
Available paired bio-specimens consisted of resected pri-
mary tumours and regional lymph node metastases, and
large needle biopsies from distant metastases as shown in
Figure 1. Some of the bio-specimens contained limited
tumour tissue allowing only the EGFL7 or miRNA-126
analysis.
All histological samples followed routine formaldehyde
fixation and paraffin embedding (FFPE) and were stored
and transported at room temperature. The median stor-
age time from sampling to analysis was 5.7 years. All
FFPE tissue blocks were processed at the Department of
Pathology, Vejle Hospital, Denmark. Tissue sections for
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adjacently from the same FFPE tissue block.
EGFL7 immunostaining
Tissue sections were stained with an anti-EGFL7 antibody
as previously described [14]. Tissue sections, 4 μm thick,
were mounted on coated slides and dried for half an hour
at 60°C. Deparaffinisation was performed in estisol for
10 min at room temperature. Rehydration was performed
in graded alcohol solutions (99-70%). Blocking of en-
dogenous peroxidase was achieved by incubation in 3%
hydrogen peroxide for 5 min. Antigen demasking was
done by heat-induced epitope retrieval in a microwave
oven, using a TEG buffer (TRIS 10 mM, EGTA 0.5 mM,
Titriplex®-VI) at pH 9 for 10 min at 1000 W and 15 min.
at 440 W. Tris-buffered saline (TBS)/Tween pH 7.6 was
added for 5 min. after cooling at room temperature. The
anti-EGFL7 antibody was a rabbit polyclonal antibody
(ab115786, Abcam Cambridge, UK) used in a 1:200 dilu-
tion (diluted in Dako REAL Antibody Diluent, S2022) and
incubated for 90 min. (room temp.). After washing in
TBS/Tween the visualisation was accomplished using
Dako’s EnVision + System-HRP (DAB) for Rabbit Primary
Antidodies™, K4011 for 30 min. All sections were counter-
stained with Mayer haematoxylin.
The specificity of the anti-EGFL7 antibody was tested
by pre-incubation of the antibody with recombinant
EGFL7 protein. 4 μl recombinant EGFL7 (Novus Biologi-
cals H00051162-P01) and 1 μl of the anti-EGFL7 antibody
were mixed in 200 μl dilution buffer (Dako EnVision
FLEX WASH BUFFER K8007) to give approximately
2.4 μM antigen versus 0.6 μM antibody. The solution was
left for 30 min at room temperature followed by 90 min
incubation on the tissue sections. This resulted in greatly
reduced staining of ECs and abolished staining of smooth
muscle cells, adipocytes, tumour cells as well as enteric
neuronal cells and weak background staining. These ob-
servations suggest that the antibody recognise EGFL7 in
EC, and probably also one or more other similar proteins
(Additional file 1: Figure S1).
MicroRNA-126 in situ hybridization
The miRNA-126 ISH was performed essentially as previ-
ously described [29,30]. In brief, 6-μm thick tissue sections
were pre-treated with a proteinase-K solution followed by
hybridization with a double 6-carboxyfluorescein (FAM)-
labelled Locked Nucleic Acid (LNA) miRCURY probe
(LNA™microRNA detection probe, Exiqon A/S, Denmark).
After stringent washes in SSC buffers, the probes were
detected with alkaline phosphatise-conjugated sheep anti-
FAM Fab fragments (Roche). The 4-nitro-blue tetrazo-
lium (NBT) and 5-brom-4-chloro-3′-Indolyl-phosphate
(BCIP) substrate (Roche) were added and samples were
incubated leading to a blue precipitate (the ISH signal).Counterstaining was performed with nuclear fast red.
All slides were processed in a Tecan Freedom Evo auto-
mated hybridization instrument (Tecan, Männedorf,
Switzerland) [30] in series of 48 slides per run.
EGFL7 and microRNA-126 image analyses
Image acquisition and analysis was carried out according
to the methodology previously described [14].
EGFL7: Image analysis was performed using the
Visiopharm integrated microscope and software module
(Visiopharm, Hørsholm, Denmark). Whole slide images
were obtained for each slide using x1.5 objective. The
tumour area was encircled in order to obtain random, sys-
tematic sampling of x20 images (x282 total magnification
on the computer monitor) for quantification of the EGFL7
expression. Two image acquisition configurations were
applied depending on whether the samples were whole
tumour resections, lymph nodes or large needle biopsies.
For tumour resections, up to 25 non-overlapping x20 im-
ages per sample were collected. All images were within
the tumour tissue compartment. For large needle biopsies,
x20 images were collected to cover the whole tissue area.
A fraction of the images contained limited tumour tissue
compartments. The pixel classifier prepared for the
tumour resections generated estimates of the EGFL7 ex-
pression that were 11% higher than those obtained from
the large needle biopsy specific classifier, probably due to
increased area contribution from empty glands associated
with smaller biopsies. A factor 1.11 was consequently used
to correct for these estimates. To allow direct comparison
between the estimates of EGFL7 expression from resec-
tion samples and the biopsy samples, all estimates were
calculated as [[area of stained ECs]*[1.11]]/[total tissue
area detected]. The total tissue area detected also included
nuclei and connective tissue, as mean values of x20 images
for each patient. Thus, the estimates of EGFL7 expression
are presented as vessel area fractions (VA) without a di-
mension. Strong DAB staining was only seen in EC while
faint and sporadic DAB staining was detected in some
other cell types that resulted in a minor contribution to
the EGFL7 estimate. The threshold of the classifier was
thus adjusted to count only the strong DAB signal result-
ing in an estimate virtually specific for EC expression of
EGFL7. The staining of the large needle biopsies resulted
in expression of more widespread background levels in a
few samples. Images with tumour ulceration and necrotic
tissue, staining artefacts, and those with no cancer cells
were excluded.
MicroRNA-126: Image acquisition and analysis was
achieved using the same principles as described for
EGFL7 with a few exceptions. The colour classifier was
prepared to determine the area fraction represented by
the blue miRNA-126 ISH signal. As for the EGFL7, only
the strong ISH signals were included in the quantitative
Hansen et al. Journal of Translational Medicine  (2015) 13:10 Page 4 of 9estimates and the mean score of VA fractions from the
sampled images, and calculated for each patient as de-
scribed for EGFL7. The image analysis protocols were
performed by one observer (BSN) unaware of the clinical
setting.
Statistics
Median values were compared using the Wilcoxon rank
sum test. Fisher’s exact test was used for comparison
between categorical parameters, and linear regression
analysis was used to investigate the linear association
between continuous variables. All statistical calculations
were carried out using the NCSS statistical software
(NCSS Statistical Software, Kaysville, UT 84037, USA,
version 2007). P values < 0.05 were considered significant,
and all tests were two-sided.
Results
The intra-tumoural expressions of EGFL7- and miRNA-126
were successfully visualised in all tissue samples. Repre-
sentative images of the EGFL7 immunoperoxidase staining
and the miRNA-126 ISH signal and their corresponding
classified images used to obtain quantitative estimates of
VA are demonstrated in Figure 2. The EGFL7 immunoper-
oxidase resulted in intense staining of ECs (cytoplasm and
cell membrane), and rather faint signals in smooth muscleFigure 2 Visualisation of EGFL7 and miRNA-126. Representative images
Domain 7 (EGFL7), by immunohistochemical analysis, showing staining of e
(Ac) demonstrating intense staining of ECs (green) and faint staining (dark
quantitative estimate. (B) The microRNA-126 (miRNA-126) in situ hybridizati
of ECs (blue) and the corresponding classified image (Bc) demonstrating thcells, adipocytes, enteric neurons and sometimes cancer
cells (Figure 2A). The miRNA-126 probe resulted in an
intense ISH signal in blood vessels and weaker staining in
other tissue structures, which was considered unspecific
(Figure 2B).
Patients
Patient characteristics according to stage and relapse are
shown in Table 1. Though pre-selected for post surgical
relapse or 6-year relapse free survival, patients with stage
II-III disease were comparable regarding the standard
clinico-pathological characteristics (p > 0.25).
Primary tumours
The median estimates of intra-tumoural EGFL7 and
miRNA-126 VA in primary tumours according to stage
and relapse are shown in Table 1. The median EGFL7
VA was significantly higher in patients with recurrent
disease compared to patients with stage II (p = 0.02)
and stage III (p = 0.001), without relapse. There was no
significant difference in the median EGFL7 VA of the
primary tumours between patients with nonrecurring
stage II and III, or between patients with recurring
stage II or III and stage IV. There were no significant
differences in median miRNA-126 VA between the
patient groups.of (A): the intra-tumoural expression of Epidermal Growth Factor-like
ndothelial cells (ECs, brown) and the corresponding classified image
green) of myofibroblasts. Only the intense signal was included in the
on (ISH) analysis, showing merely exclusive intra-tumoural expression
e ECs included in the quantitative estimate (green).
Table 1 Clinico-pathologic characteristics according to disease stage and relapse (N = 126)
Parameter Stage of disease at time of operation
Stage II Stage III Stage IV
Relapse free Relapsed Relapse free Relapsed
N = 20 (%) N = 13 (%) N = 20 (%) N = 19 (%) N = 54 (%)
Gender
Male 12 (60) 7 (54) 9 (45) 10 (53) 22 (41)
Female 8 (40) 6 (46) 11 (55) 9 (47) 32 (59)
Age
Median 70 65 66 66 64
Range 54-84 44-76 48-87 45-73 25-79
Location
Colon 12 (60) 11 (85) 14 (70) 12 (63) 45 (83)
Rectum 8 (40) 2 (15) 6 (30) 7 (37) 9 (17)
T category
1-3 19 (95) 12 (92) 18 (90) 16 (84) 27 (50)
4 1 (5) 1 (8) 2 (10) 3 (16) 27 (50)
Malignancy gradea
High 3 (15) 2 (18) 5 (25) 2 (18) 12 (26)
Low +medium 17 (85) 9 (82) 15 (75) 9 (82) 34 (74)
Vascular invasiona
Yes 2 (11) 2 (22) 2 (11) 1 (13) 24 (55)
No 16 (89) 7 (78) 17 (89) 7 (88) 20 (45)
Neuronal invasiona
Yes 1 (10) 1 (11) 4 (20) 1 (13) 14 (42)
No 9 (90) 8 (89) 16 (80) 7 (88) 19 (58)
EGFL7 VAb
Median (95% CI) 2.9 (1.9-4.9) 5.0 (3.0-9.0) 3.0 (1.4-4.1) 6.0 (4.0-9.0) 7.0 (4.0-9.0)
miRNA-1276 VA
Median (95% CI) 6.7 (5.6-9.9) 4.3 (4.0-8.9) 6.0 (4.0-8.0) 6.9 (4.8-11.8) 8.6 (5.3-10.8)
CI: Confidence interval.
aNot assessed for all patients.
bEstimates of vessel area fraction.
Not all numbers in the parentheses equal 100 due to rounding of data.
The median, intra-tumoural EGFL7 VA was significantly higher in patients with relapsing disease compared to corresponding patients with stage II (p = 0.02) and
stage III (p = 0.001), without relapse.
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stage and clinical course are shown in Figure 3.
Significant correlations between VA estimates of
EGFL7 and miRNA-126 were demonstrated in patients
with stage III disease, relapsed or without relapse, and
stage IV, respectively (Additional file 2: Figure S2 A-E).
Regional lymph node metastases
The median of EGFL7 and miRNA-126 VA estimates in
paired samples of primary tumours and regional lymph
node metastases are shown in Table 2. The differences
between expressions in primary tumours and regional
lymph node metastases were significant regarding both
parameters with the EGFL7 demonstrating higher VA inthe regional lymph node metastases and the miRNA-126
lower VA, compared to the primary tumours, respectively.
A borderline significant correlation was detected between
estimates of EGFL7 and miRNA-126 VA in the regional
lymph node metastases (Additional file 2: Figure S2 F).
No significant correlations were detected between the
VA of EGFL7 and miRNA-126 in primary tumours and
regional lymph node metastases, r = 0.15, p = 0.32, and
r = 0.17, p = 0.24, respectively.
Distant metastases
The median of EGFL7 and miRNA-126 VA estimates
according to location of distant metastases are shown in
Additional file 3: Table S1. The median miRNA-126 VA
Figure 3 Dot plot illustrating the intra-tumoural expressions of
Epidermal Growth Factor-like Domain 7 (EGFL7) in primary
tumours according to stage (St.) and relapse free (−R) and
relapsed (+R) patients, respectively (N = 123). See Table 2 for
statistical differences between the medians (represented by black bars).
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toneal metastases (p = 0.047).
For statistical power, only the VA estimates of EGFL7
and miRNA-126 in the liver metastases were compared
with the corresponding expressions in the regional lymph
node metastases and the primary tumours. The median
miRNA-126 VA was significantly lower in liver metastases
than in the primary tumours, p = 0.02 (Table 2). Further-
more, a positive significant correlation between estimates of
EGFL7 and miRNA-126 VA was detected in the liver me-
tastases, r = 0.55, p = 0.02 (Additional file 2: Figure S2 G).
No significant correlations were found comparing estimates
of EGFL7 and miRNA-126 VA in primary tumours and
liver metastases, r = −0.26, p = 0.41, and r = −0.01, p = 0.97,
respectively.
Discussion
In the present descriptive study we describe the expression
of EC-associated EGFL7 and miRNA-126 by estimating theTable 2 Epidermal growth factor-like domain 7 (EGFL7) and mi
and associated lymph node/distant metastases
Parameter EGFL7 vessel area
Number Median CI p
Primary tumours 48 7.0 (4.0-9.0) 0
Lymph nodes 48 9.0 (7.0-13.0)
Primary tumours 12 5.5 (4.0-15.0) 0
Liver metastases 12 6.7 (2.0-15.0)
Lymph nodes 6 12.5 (2.0-21.0) 0
Liver metastases 6 9.8 (0.5-25)
CI: Confidence interval.
Numbers differ in the comparisons depending on the availability of paired samplesvessel area fractions in primary tumours of different stages
and in paired samples of primary tumours, regional lymph
node metastases, and distant metastases from patients with
CRC. The results may suggest a possible clinical import-
ance of EGFL7 at early disease stages and a coordinated
regulation of this angiogenic couple in localised as well as
metastatic disease.
From the methodological point of view one may question
whether the obtained VA estimates of EGFL7 and miRNA-
126 in the present study are really different from traditional
estimates of e.g. microvessel density (MVD) as obtained by
CD31 and/or CD34 IHC. However, the MVD estimate is
often based on hot-spot sampling, whereas the methodo-
logical approach in the present study is based on random,
systematic sampling quantifying the intra-tumoural expres-
sions of EGLF7 and miRNA-126 within the whole tumour
area. In addition, being area fractions, the VAs do not repre-
sent numerical densities, but are relative fraction estimates
for the individual tumours. Both CD31 and CD34 play a role
in cellular adhesion and angiogenesis, but can often be de-
tected in mesenchymal and bone marrow-derived cells in
addition to the ECs, which may contribute to bias in MVD
estimates. Our image analysis and sampling approach, based
on intensity thresholds, diminished the contribution from
mesenchymal cells to the VA estimates. On the other hand,
EGLF7 is important for vascular tubulogenesis [6] and per-
meability [10]. Moreover, being highly specific for ECs
[15,16], miRNA-126 participates in regulating EC prolifera-
tion, migration, and survival [17-20], and takes part in
adjusting blood vessel integrity and thus the extravasation of
inflammatory cells into the tumour compartment [17,18,21].
Thus, a range of functional aspects are associated with
EGLF7 and miRNA-126, which are unrelated to that of
CD31 and/or CD34. We have previously reported that
MVD estimates of CD34- correlate with that of miRNA-
126- [27], but the association between the parameters was
weak.
The EGFL7 immunoperoxidase staining showed an
intense staining of EC, but also faint signals in other cell
populations, including adipocytes, smooth muscle cells,croRNA-126 (miRNA-126) expressions in primary tumours
miRNA-126 vessel area
-value Number Median CI p-value
.01 51 8.6 (5.3-10.8) <10−6
51 2.7 (2.1-3.4)
.84 13 11.4 (4.8-16.1) 0.02
13 5.1 (2.6-7.3)
.83 6 2.2 (0.1-4.5) 0.06
6 6.3 (2.6-8.0)
. Bold data indicates significant p-values.
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since miRNA-126 is located within the EGFL7 precursor
transcript and therefore high concordance in the expres-
sion patterns between the two is to be expected. However,
it should be noted that expression of EGFL7 has been re-
ported by others in cancer cells [12,13] and neurons [31].
Importantly, however, it was clear that the strongest
EGFL7 signal was seen in ECs and the implementation of
a signal intensity threshold in the image analysis, and
restricting quantification within the tumour area, enabled
us to obtain estimates of tumour-derived blood vessel spe-
cific EGFL7 expression. The miRNA-126 ISH signal was
generally EC specific in both the primary tumours and
metastatic lesions, in accordance with our previous find-
ings [27]. Our observation that EGFL7 immunostaining
was seen in non-EC cells questions the specificity of the
EGFL7 antibody employed. Our antibody specificity test
suggested that the antibody specifically reacted with the
other cell populations, including adipocytes, smooth
muscle cells, and cancer cells. If EGFL7 expression is EC
specific, this observation implies that the antibody cross-
reacts with one or more similar proteins expressed in
those cell populations. On the other hand, if the EGFL7
immunostaining observed in the non-EC compartments
represents genuine EGFL7, the different expression pat-
terns between EGFL7 and miRNA-126 suggest differential
post-transcriptional processing involving parallel EGFL7
biosynthesis and miRNA-126 degradation, as also dis-
cussed further below. Future studies employing more and
highly specific anti-EGFL-7 antibodies will be required to
address this important question.
Estimates of EGFL7 VA in primary tumours of stages II
and III were significantly higher in the case of relapsing
disease and primarily disseminated tumours (stage IV),
compared to tumours without relapse. These results indi-
cate a possible role of EGFL7 in the metastatic process of
CRC cells at an early disease stage. This is in accordance
with EGFL7 functioning as a pro-angiogenic protein en-
hancing tumour growth and potentially also dissemination
of tumour cells [10,32,33]. We were unable to identify pre-
vious studies analysing the protein expression of EGFL7 in
early stage CRC. One study, however, by Díaz et al. ana-
lysed the EGFL7 mRNA expression in 110 patients with
CRC stage I-IV, and demonstrated a significantly higher
EGFL7 mRNA expression in stage III and IV than in stage
I and II tumours, which supports the present results [11].
Furthermore, pre-clinical studies have demonstrated a re-
lationship between high EGFL7 expression and increased
risk of metastatic spread in hepatocellular, breast, and lung
cancer [10,12]. A similar relationship has been demon-
strated by analysing EGFL7, using IHC in samples from
patients with laryngeal carcinomas [13].
On the other hand, we found no significant differences
in VA estimates of miRNA-126 in the primary tumoursaccording to disease stage or relapse. Previous studies in
CRC have shown divergent results indicating prognostic
as well as no prognostic impact of miRNA-126 in early
disease stages. Moreover, a higher as well as a lower ex-
pression of miRNA-126 in CRC tissue compared to nor-
mal colonic tissue have been reported [11,23,24,26,34].
There may be multiple explanations such as differences in
the methodological approach, sample sizes, tissue used for
analyses, quantification methods, normalisation procedures
etc., which are all known to influence the final results [27].
Also, the multiple known targets of miRNA-126 may blur
the results of the present analysis or perhaps miRNA-126
is more important (as a biomarker) in the metastatic set-
ting than at earlier disease stages in this particular context.
A positive significant correlation was demonstrated
between the VA estimates of EGFL7 and miRNA-126 in
stage III and IV tumours. Since the miR-126 sequence is
located within the EGFL7 mRNA precursor, some degree
of correlation in expression levels would be expected,
although we are here considering the EGFL7 protein and
the miRNA-126 (transcript). Some investigators have
found a positive correlation between EGFL7 and miR-126
[16,35-37], others have, interestingly, been unable to
detect such an association [11,16], which supports the lack
of significant correlation in the present study.
The VA estimates of EGFL7 were significantly higher,
and the estimates of miRNA-126 significantly lower, in
regional lymph node metastases than in primary tumours.
This corresponds rather well with the assumption of high
EGFL7 and low miRNA-126 expressions being associated
with an increased metastatic potential. The correlation
between VA estimates of EGFL7 and miRNA-126 in the
lymph node metastases only reached borderline signifi-
cance, tentatively supporting a positive correlation between
the estimates. We were unable to identify previous studies
assessing estimates of EGFL7 and miRNA-126 expression
in paired samples of primary CRC and lymph node
metastases.
In the present study VA estimates of EGFL7 and
miRNA-126 were obtainable from all analysed metastatic
lesions at different organ sites. Although VA estimates of
miRNA-126 differed significantly between lung and peri-
toneal metastases, further comparisons were restricted
to liver metastases for reasons of statistical power. We
detected no differences between VA estimates of EGFL7
in the liver metastases and primary tumours or regional
lymph node metastases. However, the VA estimates of the
miRNA-126 were significantly lower in liver metastases
than in primary tumours. This finding is comparable with
the difference between primary tumours and regional
lymph nodes, suggesting a general down-regulation of the
miRNA-126 expression in metastatic lesions. This is con-
sistent with previous reports on breast cancer, where
miRNA-126 has been documented to be down-regulated
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[36,38,39]. A possible difference, although non-significant,
was also detected between VA estimates of miRNA-126 in
liver and regional lymph node metastases. These results
are in line with the study by Png et al. in which a suppress-
ing role of metastatic initiation and metastatic colonization
was demonstrated for miRNA-126 [39]. These effects were
mediated through suppression of EC recruitment to the
metastatic lesions caused by suppression of the IGFBP2,
PITPNCI, and MERTK genes. Together with the results
obtained in the primary tumours, these data may indi-
cate that EGLF7 and miRNA-126 exert their angiogenic
influences differently, depending on the stage of the
disease. In accordance with the above comparisons a
positive significant correlation between VA estimates of
EGFL7 and miRNA-126 was seen in liver metastases,
suggesting a conserved regulation of their common
expression at the distant metastatic organ site.
Conclusion
The current descriptive study holds the natural limitations
of a retrospective investigation and the results are hypoth-
esis generating. However, the present design with paired
samples adds information on the examined biomarkers in
a clinical setting, which is rarely available in translational
research. Overall, the results correspond rather well with
the assumption of high EGFL7 and low miRNA-126
expressions being associated with an increased metastatic
potential.
 The results argue for a potential role of EGFL7 in
the early metastatic process leading to relapse after
curatively intended surgery for stage II and III CRC
and call for further clinical validation.
 A pronounced down-regulation of miRNA-126 in
metastatic lesions compared to the primary tumour
was detected supporting its role in the metastatic
process.
 The present results demonstrated a significant
correlation between the VA estimates of EGFL7 and
miRNA-126 in advanced stages supporting a
coordinated regulation of their expression.
 The visualisation of EGFL7 suggested an expression
pattern with a high EC affinity, however, expression
in other cell types is suggested. This observation
requires further investigation.
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